Emilia Bagiella

Search results

• Data on COVID-19 Discussed by Researchers at Icahn School of Medicine (A Randomized Trial of Mesenchymal Stromal Cells for Moderate To Severe Acute Respiratory Distress Syndrome From Covid-19)

  Alan Moskowitz, Jessica Overbey, Emilia Bagiella & Keren Osman

  3/04/23

  1 item of Media coverage

  Press/Media

• -Simultaneous Repair of Heart Valves May Benefit Some Adults

  Alan Moskowitz, Jessica Overbey, Emilia Bagiella & Annetine Gelijns

  17/11/21

  1 item of Media coverage

  Press/Media

• The Johns Hopkins Health System: Simultaneous Repair of Heart Valves May Benefit Some Adults

  Alan Moskowitz, Jessica Overbey, Emilia Bagiella & Annetine Gelijns

  16/11/21

  1 item of Media coverage

  Press/Media

• Simultaneous repair of heart valves may benefit some adults

  Alan Moskowitz, Jessica Overbey, Emilia Bagiella & Annetine Gelijns

  16/11/21

  4 items of Media coverage

  Press/Media

• Mesoblast Limited: FIRST PATIENTS DOSED IN PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF MESOBLAST’S REMESTEMCEL-L FOR COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME

  Alan Moskowitz, Emilia Bagiella & Annetine Gelijns

  7/05/20

  1 item of Media coverage

  Press/Media

• MESOBLAST LIMITED : - First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS

  Alan Moskowitz, Emilia Bagiella & Annetine Gelijns

  7/05/20

  2 items of Media coverage

  Press/Media

• First patients dosed in Mesoblast COVID-19 trial

  Alan Moskowitz, Emilia Bagiella & Annetine Gelijns

  7/05/20

  1 item of Media coverage

  Press/Media

• MESOBLAST : First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS

  Alan Moskowitz, Emilia Bagiella & Annetine Gelijns

  6/05/20

  1 item of Media coverage

  Press/Media

• First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Australian Stock Exchange:MSB.AX

  Alan Moskowitz, Emilia Bagiella & Annetine Gelijns

  6/05/20

  1 item of Media coverage

  Press/Media

• First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome

  Alan Moskowitz, Emilia Bagiella & Annetine Gelijns

  5/05/20 → 6/05/20

  22 items of Media coverage

  Press/Media

• First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome

  Alan Moskowitz, Emilia Bagiella & Annetine Gelijns

  6/05/20

  1 item of Media coverage

  Press/Media

• First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome

  Alan Moskowitz, Emilia Bagiella & Annetine Gelijns

  6/05/20

  1 item of Media coverage

  Press/Media

• Mount Sinai Health System Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients

  Alan Moskowitz, Emilia Bagiella, Keren Osman, John Levine & Annetine Gelijns

  10/04/20

  1 item of Media coverage

  Press/Media

• Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients

  Alan Moskowitz, John Levine, Emilia Bagiella, Keren Osman & Annetine Gelijns

  10/04/20

  1 item of Media coverage

  Press/Media

• Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients

  Alan Moskowitz, Emilia Bagiella, Keren Osman, John Levine & Annetine Gelijns

  10/04/20

  2 items of Media coverage

  Press/Media

• Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes; STANCE

  Emilia Bagiella & J Mocco,

  2/10/18

  1 item of Media coverage

  Press/Media

• Hybrid Coronary Revascularization Trial

  Alan Moskowitz, Emilia Bagiella & John Puskas

  2/10/18

  1 item of Media coverage

  Press/Media